1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 Alpha-glucosidase Inhibitors 1.2.3 Amylin Agonists 1.2.4 Biguanides 1.2.5 Dipeptidyl Peptidase-4 (DPP4) Inhibitors 1.2.6 Glinides / Meglitinides 1.2.7 GLP-1 Analogs / GLP-1 Agonists 1.2.8 Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors 1.2.9 Sulfonylureas 1.2.10 Thiazolidinediones 1.2.11 Others 1.3 Market by Application 1.3.1 Global Non-Insulin Therapies for Diabetes Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Monitoring 1.3.3 Diagnosis 1.3.4 Treatment 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Non-Insulin Therapies for Diabetes Market Perspective (2016-2027) 2.2 Non-Insulin Therapies for Diabetes Growth Trends by Regions 2.2.1 Non-Insulin Therapies for Diabetes Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 Non-Insulin Therapies for Diabetes Historic Market Share by Regions (2016-2021) 2.2.3 Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2022-2027) 2.3 Non-Insulin Therapies for Diabetes Industry Dynamic 2.3.1 Non-Insulin Therapies for Diabetes Market Trends 2.3.2 Non-Insulin Therapies for Diabetes Market Drivers 2.3.3 Non-Insulin Therapies for Diabetes Market Challenges 2.3.4 Non-Insulin Therapies for Diabetes Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue 3.1.1 Global Top Non-Insulin Therapies for Diabetes Players by Revenue (2016-2021) 3.1.2 Global Non-Insulin Therapies for Diabetes Revenue Market Share by Players (2016-2021) 3.2 Global Non-Insulin Therapies for Diabetes Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Non-Insulin Therapies for Diabetes Revenue 3.4 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio 3.4.1 Global Non-Insulin Therapies for Diabetes Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Non-Insulin Therapies for Diabetes Revenue in 2020 3.5 Non-Insulin Therapies for Diabetes Key Players Head office and Area Served 3.6 Key Players Non-Insulin Therapies for Diabetes Product Solution and Service 3.7 Date of Enter into Non-Insulin Therapies for Diabetes Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Non-Insulin Therapies for Diabetes Breakdown Data by Type 4.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Type (2016-2021) 4.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2022-2027) 5 Non-Insulin Therapies for Diabetes Breakdown Data by Application 5.1 Global Non-Insulin Therapies for Diabetes Historic Market Size by Application (2016-2021) 5.2 Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America Non-Insulin Therapies for Diabetes Market Size (2016-2027) 6.2 North America Non-Insulin Therapies for Diabetes Market Size by Type 6.2.1 North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) 6.2.2 North America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) 6.2.3 North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027) 6.3 North America Non-Insulin Therapies for Diabetes Market Size by Application 6.3.1 North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) 6.3.2 North America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) 6.3.3 North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027) 6.4 North America Non-Insulin Therapies for Diabetes Market Size by Country 6.4.1 North America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) 6.4.2 North America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe Non-Insulin Therapies for Diabetes Market Size (2016-2027) 7.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type 7.2.1 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) 7.2.2 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) 7.2.3 Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027) 7.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application 7.3.1 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) 7.3.2 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) 7.3.3 Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027) 7.4 Europe Non-Insulin Therapies for Diabetes Market Size by Country 7.4.1 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) 7.4.2 Europe Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size (2016-2027) 8.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type 8.2.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) 8.2.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) 8.2.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027) 8.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application 8.3.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) 8.3.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) 8.3.3 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027) 8.4 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region 8.4.1 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2016-2021) 8.4.2 Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Non-Insulin Therapies for Diabetes Market Size (2016-2027) 9.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type 9.2.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) 9.2.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) 9.2.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027) 9.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application 9.3.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) 9.3.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) 9.3.3 Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027) 9.4 Latin America Non-Insulin Therapies for Diabetes Market Size by Country 9.4.1 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) 9.4.2 Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size (2016-2027) 10.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type 10.2.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) 10.2.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) 10.2.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2027) 10.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application 10.3.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) 10.3.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) 10.3.3 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2027) 10.4 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country 10.4.1 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) 10.4.2 Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 GSK 11.1.1 GSK Company Details 11.1.2 GSK Business Overview 11.1.3 GSK Non-Insulin Therapies for Diabetes Introduction 11.1.4 GSK Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.1.5 GSK Recent Development 11.2 Eli Lilly 11.2.1 Eli Lilly Company Details 11.2.2 Eli Lilly Business Overview 11.2.3 Eli Lilly Non-Insulin Therapies for Diabetes Introduction 11.2.4 Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.2.5 Eli Lilly Recent Development 11.3 Sumitomo Dainippon Pharma 11.3.1 Sumitomo Dainippon Pharma Company Details 11.3.2 Sumitomo Dainippon Pharma Business Overview 11.3.3 Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Introduction 11.3.4 Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.3.5 Sumitomo Dainippon Pharma Recent Development 11.4 Intarcia Therapeutics 11.4.1 Intarcia Therapeutics Company Details 11.4.2 Intarcia Therapeutics Business Overview 11.4.3 Intarcia Therapeutics Non-Insulin Therapies for Diabetes Introduction 11.4.4 Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.4.5 Intarcia Therapeutics Recent Development 11.5 Servier 11.5.1 Servier Company Details 11.5.2 Servier Business Overview 11.5.3 Servier Non-Insulin Therapies for Diabetes Introduction 11.5.4 Servier Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.5.5 Servier Recent Development 11.6 Pfizer 11.6.1 Pfizer Company Details 11.6.2 Pfizer Business Overview 11.6.3 Pfizer Non-Insulin Therapies for Diabetes Introduction 11.6.4 Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.6.5 Pfizer Recent Development 11.7 Merck 11.7.1 Merck Company Details 11.7.2 Merck Business Overview 11.7.3 Merck Non-Insulin Therapies for Diabetes Introduction 11.7.4 Merck Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.7.5 Merck Recent Development 11.8 Dong-A Pharmaceutical 11.8.1 Dong-A Pharmaceutical Company Details 11.8.2 Dong-A Pharmaceutical Business Overview 11.8.3 Dong-A Pharmaceutical Non-Insulin Therapies for Diabetes Introduction 11.8.4 Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.8.5 Dong-A Pharmaceutical Recent Development 11.9 Luye Pharma Group 11.9.1 Luye Pharma Group Company Details 11.9.2 Luye Pharma Group Business Overview 11.9.3 Luye Pharma Group Non-Insulin Therapies for Diabetes Introduction 11.9.4 Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.9.5 Luye Pharma Group Recent Development 11.10 Eurofarma 11.10.1 Eurofarma Company Details 11.10.2 Eurofarma Business Overview 11.10.3 Eurofarma Non-Insulin Therapies for Diabetes Introduction 11.10.4 Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.10.5 Eurofarma Recent Development 11.11 Geropharm 11.11.1 Geropharm Company Details 11.11.2 Geropharm Business Overview 11.11.3 Geropharm Non-Insulin Therapies for Diabetes Introduction 11.11.4 Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.11.5 Geropharm Recent Development 11.12 Alkem Labs 11.12.1 Alkem Labs Company Details 11.12.2 Alkem Labs Business Overview 11.12.3 Alkem Labs Non-Insulin Therapies for Diabetes Introduction 11.12.4 Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.12.5 Alkem Labs Recent Development 11.13 SatRx 11.13.1 SatRx Company Details 11.13.2 SatRx Business Overview 11.13.3 SatRx Non-Insulin Therapies for Diabetes Introduction 11.13.4 SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.13.5 SatRx Recent Development 11.14 Jiangsu Hansoh Pharmaceutical 11.14.1 Jiangsu Hansoh Pharmaceutical Company Details 11.14.2 Jiangsu Hansoh Pharmaceutical Business Overview 11.14.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Introduction 11.14.4 Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.14.5 Jiangsu Hansoh Pharmaceutical Recent Development 11.15 Novo Nordisk 11.15.1 Novo Nordisk Company Details 11.15.2 Novo Nordisk Business Overview 11.15.3 Novo Nordisk Non-Insulin Therapies for Diabetes Introduction 11.15.4 Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.15.5 Novo Nordisk Recent Development 11.16 Emisphere 11.16.1 Emisphere Company Details 11.16.2 Emisphere Business Overview 11.16.3 Emisphere Non-Insulin Therapies for Diabetes Introduction 11.16.4 Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.16.5 Emisphere Recent Development 11.17 Uni-Bio Science Group 11.17.1 Uni-Bio Science Group Company Details 11.17.2 Uni-Bio Science Group Business Overview 11.17.3 Uni-Bio Science Group Non-Insulin Therapies for Diabetes Introduction 11.17.4 Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.17.5 Uni-Bio Science Group Recent Development 11.18 Takeda 11.18.1 Takeda Company Details 11.18.2 Takeda Business Overview 11.18.3 Takeda Non-Insulin Therapies for Diabetes Introduction 11.18.4 Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.18.5 Takeda Recent Development 11.18 3SBio .1 3SBio Company Details .2 3SBio Business Overview .3 3SBio Non-Insulin Therapies for Diabetes Introduction .4 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) .5 3SBio Recent Development 11.20 Jiangsu Hengrui Medicine 11.20.1 Jiangsu Hengrui Medicine Company Details 11.20.2 Jiangsu Hengrui Medicine Business Overview 11.20.3 Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Introduction 11.20.4 Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) 11.20.5 Jiangsu Hengrui Medicine Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Non-Insulin Therapies for Diabetes Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of Alpha-glucosidase Inhibitors Table 3. Key Players of Amylin Agonists Table 4. Key Players of Biguanides Table 5. Key Players of Dipeptidyl Peptidase-4 (DPP4) Inhibitors Table 6. Key Players of Glinides / Meglitinides Table 7. Key Players of GLP-1 Analogs / GLP-1 Agonists Table 8. Key Players of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Table 9. Key Players of Sulfonylureas Table 10. Key Players of Thiazolidinediones Table 11. Key Players of Others Table 12. Global Non-Insulin Therapies for Diabetes Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 13. Global Non-Insulin Therapies for Diabetes Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 14. Global Non-Insulin Therapies for Diabetes Market Size by Regions (2016-2021) & (US$ Million) Table 15. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2016-2021) Table 16. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 17. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2022-2027) Table 18. Non-Insulin Therapies for Diabetes Market Trends Table 19. Non-Insulin Therapies for Diabetes Market Drivers Table 20. Non-Insulin Therapies for Diabetes Market Challenges Table 21. Non-Insulin Therapies for Diabetes Market Restraints Table 22. Global Non-Insulin Therapies for Diabetes Revenue by Players (2016-2021) & (US$ Million) Table 23. Global Non-Insulin Therapies for Diabetes Market Share by Players (2016-2021) Table 24. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2020) Table 25. Ranking of Global Top Non-Insulin Therapies for Diabetes Companies by Revenue (US$ Million) in 2020 Table 26. Global 5 Largest Players Market Share by Non-Insulin Therapies for Diabetes Revenue (CR5 and HHI) & (2016-2021) Table 27. Key Players Headquarters and Area Served Table 28. Key Players Non-Insulin Therapies for Diabetes Product Solution and Service Table 29. Date of Enter into Non-Insulin Therapies for Diabetes Market Table 30. Mergers & Acquisitions, Expansion Plans Table 31. Global Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million) Table 32. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2016-2021) Table 33. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Type (2022-2027) (US$ Million) Table 34. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2022-2027) & (US$ Million) Table 35. Global Non-Insulin Therapies for Diabetes Market Size Share by Application (2016-2021) & (US$ Million) Table 36. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2016-2021) Table 37. Global Non-Insulin Therapies for Diabetes Forecasted Market Size by Application (2022-2027) (US$ Million) Table 38. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Application (2022-2027) & (US$ Million) Table 39. North America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million) Table 40. North America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million) Table 41. North America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million) Table 42. North America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million) Table 43. North America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million) Table 44. North America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million) Table 45. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million) Table 46. Europe Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million) Table 47. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million) Table 48. Europe Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million) Table 49. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million) Table 50. Europe Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million) Table 51. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million) Table 52. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million) Table 53. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million) Table 54. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million) Table 55. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2016-2021) & (US$ Million) Table 56. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size by Region (2022-2027) & (US$ Million) Table 57. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million) Table 58. Latin America Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million) Table 59. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million) Table 60. Latin America Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million) Table 61. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million) Table 62. Latin America Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million) Table 63. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2016-2021) (US$ Million) Table 64. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Type (2022-2027) & (US$ Million) Table 65. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2016-2021) (US$ Million) Table 66. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Application (2022-2027) & (US$ Million) Table 67. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2016-2021) & (US$ Million) Table 68. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size by Country (2022-2027) & (US$ Million) Table 69. GSK Company Details Table 70. GSK Business Overview Table 71. GSK Non-Insulin Therapies for Diabetes Product Table 72. GSK Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 73. GSK Recent Development Table 74. Eli Lilly Company Details Table 75. Eli Lilly Business Overview Table 76. Eli Lilly Non-Insulin Therapies for Diabetes Product Table 77. Eli Lilly Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 78. Eli Lilly Recent Development Table 79. Sumitomo Dainippon Pharma Company Details Table 80. Sumitomo Dainippon Pharma Business Overview Table 81. Sumitomo Dainippon Pharma Non-Insulin Therapies for Diabetes Product Table 82. Sumitomo Dainippon Pharma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 83. Sumitomo Dainippon Pharma Recent Development Table 84. Intarcia Therapeutics Company Details Table 85. Intarcia Therapeutics Business Overview Table 86. Intarcia Therapeutics Non-Insulin Therapies for Diabetes Product Table 87. Intarcia Therapeutics Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 88. Intarcia Therapeutics Recent Development Table 89. Servier Company Details Table 90. Servier Business Overview Table 91. Servier Non-Insulin Therapies for Diabetes Product Table 92. Servier Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 93. Servier Recent Development Table 94. Pfizer Company Details Table 95. Pfizer Business Overview Table 96. Pfizer Non-Insulin Therapies for Diabetes Product Table 97. Pfizer Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 98. Pfizer Recent Development Table 99. Merck Company Details Table 100. Merck Business Overview Table 101. Merck Non-Insulin Therapies for Diabetes Product Table 102. Merck Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 103. Merck Recent Development Table 104. Dong-A Pharmaceutical Company Details Table 105. Dong-A Pharmaceutical Business Overview Table 106. Dong-A Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 107. Dong-A Pharmaceutical Recent Development Table 108. Luye Pharma Group Company Details Table 109. Luye Pharma Group Business Overview Table 110. Luye Pharma Group Non-Insulin Therapies for Diabetes Product Table 111. Luye Pharma Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 112. Luye Pharma Group Recent Development Table 113. Eurofarma Company Details Table 114. Eurofarma Business Overview Table 115. Eurofarma Non-Insulin Therapies for Diabetes Product Table 116. Eurofarma Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 117. Eurofarma Recent Development Table 118. Geropharm Company Details Table 119. Geropharm Business Overview Table 120. Geropharm Non-Insulin Therapies for Diabetes Product Table 121. Geropharm Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 122. Geropharm Recent Development Table 123. Alkem Labs Company Details Table 124. Alkem Labs Business Overview Table 125. Alkem Labs Non-Insulin Therapies for Diabetes Product Table 126. Alkem Labs Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 127. Alkem Labs Recent Development Table 128. SatRx Company Details Table 129. SatRx Business Overview Table 130. SatRx Non-Insulin Therapies for Diabetes Product Table 131. SatRx Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 132. SatRx Recent Development Table 133. Jiangsu Hansoh Pharmaceutical Company Details Table 134. Jiangsu Hansoh Pharmaceutical Business Overview Table 135. Jiangsu Hansoh Pharmaceutical Non-Insulin Therapies for Diabetes Product Table 136. Jiangsu Hansoh Pharmaceutical Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 137. Jiangsu Hansoh Pharmaceutical Recent Development Table 138. Novo Nordisk Company Details Table 139. Novo Nordisk Business Overview Table 140. Novo Nordisk Non-Insulin Therapies for Diabetes Product Table 141. Novo Nordisk Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 142. Novo Nordisk Recent Development Table 143. Emisphere Company Details Table 144. Emisphere Business Overview Table 145. Emisphere Non-Insulin Therapies for Diabetes Product Table 146. Emisphere Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 147. Emisphere Recent Development Table 148. Uni-Bio Science Group Company Details Table 149. Uni-Bio Science Group Business Overview Table 150. Uni-Bio Science Group Non-Insulin Therapies for Diabetes Product Table 151. Uni-Bio Science Group Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 152. Uni-Bio Science Group Recent Development Table 153. Takeda Company Details Table 154. Takeda Business Overview Table 155. Takeda Non-Insulin Therapies for Diabetes Product Table 156. Takeda Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 157. Takeda Recent Development Table 158. 3SBio Company Details Table 159. 3SBio Business Overview Table 160. 3SBio Non-Insulin Therapies for Diabetes Product Table 161. 3SBio Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 162. 3SBio Recent Development Table 163. Jiangsu Hengrui Medicine Company Details Table 164. Jiangsu Hengrui Medicine Business Overview Table 165. Jiangsu Hengrui Medicine Non-Insulin Therapies for Diabetes Product Table 166. Jiangsu Hengrui Medicine Revenue in Non-Insulin Therapies for Diabetes Business (2016-2021) & (US$ Million) Table 167. Jiangsu Hengrui Medicine Recent Development Table 168. Research Programs/Design for This Report Table 169. Key Data Information from Secondary Sources Table 170. Key Data Information from Primary Sources List of Figures Figure 1. Global Non-Insulin Therapies for Diabetes Market Share by Type: 2020 VS 2027 Figure 2. Alpha-glucosidase Inhibitors Features Figure 3. Amylin Agonists Features Figure 4. Biguanides Features Figure 5. Dipeptidyl Peptidase-4 (DPP4) Inhibitors Features Figure 6. Glinides / Meglitinides Features Figure 7. GLP-1 Analogs / GLP-1 Agonists Features Figure 8. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Features Figure 9. Sulfonylureas Features Figure 10. Thiazolidinediones Features Figure 11. Others Features Figure 12. Global Non-Insulin Therapies for Diabetes Market Share by Application: 2020 VS 2027 Figure 13. Monitoring Case Studies Figure 14. Diagnosis Case Studies Figure 15. Treatment Case Studies Figure 16. Others Case Studies Figure 17. Non-Insulin Therapies for Diabetes Report Years Considered Figure 18. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 19. Global Non-Insulin Therapies for Diabetes Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 20. Global Non-Insulin Therapies for Diabetes Market Share by Regions: 2020 VS 2027 Figure 21. Global Non-Insulin Therapies for Diabetes Market Share by Regions (2022-2027) Figure 22. Global Non-Insulin Therapies for Diabetes Market Share by Players in 2020 Figure 23. Global Top Non-Insulin Therapies for Diabetes Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Insulin Therapies for Diabetes as of 2020 Figure 24. The Top 10 and 5 Players Market Share by Non-Insulin Therapies for Diabetes Revenue in 2020 Figure 25. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2016-2021) Figure 26. Global Non-Insulin Therapies for Diabetes Revenue Market Share by Type (2022-2027) Figure 27. North America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. North America Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027) Figure 29. North America Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027) Figure 30. North America Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027) Figure 31. United States Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. Canada Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. Europe Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Europe Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027) Figure 35. Europe Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027) Figure 36. Europe Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027) Figure 37. Germany Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. France Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 39. U.K. Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 40. Italy Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 41. Russia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Nordic Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. Asia-Pacific Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027) Figure 45. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027) Figure 46. Asia-Pacific Non-Insulin Therapies for Diabetes Market Share by Region (2016-2027) Figure 47. China Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Japan Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 49. South Korea Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 50. Southeast Asia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 51. India Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Australia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 53. Latin America Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Latin America Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027) Figure 55. Latin America Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027) Figure 56. Latin America Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027) Figure 57. Mexico Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Brazil Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 59. Middle East & Africa Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Type (2016-2027) Figure 61. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Application (2016-2027) Figure 62. Middle East & Africa Non-Insulin Therapies for Diabetes Market Share by Country (2016-2027) Figure 63. Turkey Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 64. Saudi Arabia Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 65. UAE Non-Insulin Therapies for Diabetes Market Size YoY Growth (2016-2027) & (US$ Million) Figure 66. GSK Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 67. Eli Lilly Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 68. Sumitomo Dainippon Pharma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 69. Intarcia Therapeutics Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 70. Servier Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 71. Pfizer Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 72. Merck Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 73. Dong-A Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 74. Luye Pharma Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 75. Eurofarma Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 76. Geropharm Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 77. Alkem Labs Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 78. SatRx Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 79. Jiangsu Hansoh Pharmaceutical Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 80. Novo Nordisk Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 81. Emisphere Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 82. Uni-Bio Science Group Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 83. Takeda Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 84. 3SBio Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 85. Jiangsu Hengrui Medicine Revenue Growth Rate in Non-Insulin Therapies for Diabetes Business (2016-2021) Figure 86. Bottom-up and Top-down Approaches for This Report Figure 87. Data Triangulation Figure 88. Key Executives Interviewed

GSK Eli Lilly Sumitomo Dainippon Pharma Intarcia Therapeutics Servier Pfizer Merck Dong-A Pharmaceutical Luye Pharma Group Eurofarma Geropharm Alkem Labs SatRx Jiangsu Hansoh Pharmaceutical Novo Nordisk Emisphere Uni-Bio Science Group Takeda 3SBio Jiangsu Hengrui Medicine